High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – - ASXL1 Mutations Predictably Identified in Colorectal Cancer (CRC MSI-H) and Non-Small Cell ...

SELLAS Life Sciences (SLS) announced data from preclinical studies identifying ASXL1 mutation as key predictor of SLS009, a highly selective ...

TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but ...

NP-101 plus nivolumab and ipilimumab demonstrated activity in patients with metastatic EP-NECs that were refractory to chemotherapy.

If people have had sunburn, especially as a child, skin cancer can develop and if not treated early can prove fatal ...

The following is a summary of “Phase 2 Trial of Topical Application of the Hedgehog Inhibitor Patidegib in Patients With ...

Pharmanovia partners with Lindis Biotech to commercialise catmaxomab to treat rare condition, malignant ascites: Basildon, UK Thursday, November 21, 2024, 17:00 Hrs [IST] Pharmano ...

Researchers studied the cumulative incidence and associated risk factors of keratinocyte carcinomas among patients who are survivors of childhood cancer.

Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab, a new trifunctional ...

A type of immunotherapy appears to be effective in treating a deadly subset of thyroid cancer, according to the results of a ...

The agreement gives Pharmanovia the exclusive rights to bring to market, catumaxomab, a first-in-class, trifunctional bi-specific monoclonal antibody, indicated for the intraperitoneal treatment of ...